INVEST IN THE FUTURE
AL AMYLOIDOSIS AND select immune-mediated disease CAR-T CLINICAL TRAILBLAZER
Immix Biopharma is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and select immune-mediated diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. Phase 1b/2a trial NEXICART-2 as well as the ex-U.S. study NEXICART-1.
WANT TO LEARN MORE?
Download our investor presentation to get all the latest information available.
RECENT EVENTS
RECENT NEWS
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines...
Read More
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
– Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management’s...
Read MoreImmix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will...
Read MoreImmix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already...
Read MoreINVESTOR INFORMATION NAVIGATION
LET'S BUILD SOMETHING GREAT TOGETHER
Join our newsletter for exclusive insights into groundbreaking medical advancements, the latest in research, and transformative therapies. Stay informed and be part of shaping the future of healthcare. Sign up today!
CORPORATE HIGHLIGHTS
Initiates Patient Dosing in NEXICART-2 trial
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) for US AL Amyloidosis NXC-201 clinical trial.
FDA APPROVAL OF IND APPLICATION FOR NXC-201
Opens up ability to treat patients in the US. Favorable tolerability enables potential expansion into select immune-mediated disease indications.
MULTIPLE SCIENTIFIC BOARD MEMBERS ADDED
Valuable expertise added from esteemed institutions, giving enhanced perspectives to our team
N-GENIUS CELL THERAPY PLATFORM
Possibility for additional cell therapies beyond current focus including possible expansion into select immune-mediated disease indications
FOUNDATIONAL EXCELLENCE
Paving the Way for Revolutionary Treatments
Comprehensive Clinical Foundation
Building on one of the largest clinical datasets in the CAR-T industry, Immix Biopharma has established a strong foothold in advancing CAR-T therapies.
Pivotal Tolerability Milestone
Central to this achievement is the compelling evidence from a study involving 63 myeloma patients, pivotal in establishing the favorable tolerability profile of NXC-201, even when administered at high doses.
Stepping Stone to New Therapies
This foundational data serves as a critical stepping stone for exploring broader applications, providing a robust basis for venturing into new therapeutic areas.
Opportunity in AL Amyloidosis
Such a strong safety profile is especially significant as we turn our focus towards AL Amyloidosis—a condition with no approved therapies or other therapies in development.
Validating Future Directions
The initial positive outcomes from the first 13 AL patients further validate our approach and reinforce our commitment to expanding treatment horizons.
Expanding Treatment Horizons
Building on our success with AL Amyloidosis, we’re advancing our CAR-T technology to tackle a broad array of immune-mediated diseases, extending our reach and impact.
WHERE WE ARE
By leveraging the established tolerability of NXC-201, Immix Biopharma is poised to offer new hope to patients suffering from AL Amyloidosis. The initial positive outcomes from the first AL patients treated further validate our approach and reinforce our commitment to expanding treatment horizons.
Memorial Sloan Kettering Cancer Center in NYC recently named as the lead clinical site for the NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial.
On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024
Patients Being Dosed
From December 2022 through December 2023, went from ~10 patients dosed with NXC-201 to 72 patients dosed
FDA Orphan Drug Designation
Received FDA Orphan Drug Designation for NXC-201 for AL Amyloidosis
FDA Orphan Drug Designation
Received FDA Orphan Drug Designation for NXC-201 for multiple myeloma
Publications & Presentations
Published in Haematologica, presented at the American Society for Gene and Cell Therapy, the International Myeloma Society, invited to present at the 65th American Society for Hematology
Scientific Advisor Additions
Memorial Sloan Kettering, Stanford, and Columbia University members joined Scientific Advisory Board
NXC-201 Produced for U.S. AL Amyloidosis Dosing
Produced 3 U.S. manufacturing batches of CAR-T NXC-201 for onboarding of U.S. clinical trials
NXC-201 U.S. First Patient Dosed
Dosed first patient in U.S. AL Amyloidosis clinical trial
BLUE OCEAN OPPORTUNITY
In relapsed/refractory AL Amyloidosis there are no drugs approved today (Amyloidosis is a $3 billion dollar market according to Grand View Research).
A BETTER SOLUTION
AL Amyloidosis: NXC-201 currently Phase 1b/2a clinical trial CAR-T NXC-201 in relapsed/refractory AL Amyloidosis: 92% overall response rate in clinical trials ($3B market)
Received FDA Orphan Drug Designation for NXC-201 for AL Amyloidosis. On Track to Dose NXC-201 Patients in United States.
AL AMYLOIDOSIS MARKET
INDUSTRY LEADING PARTNERS
Immix Biopharma collaborates with top-tier industry leaders to accelerate our research and development efforts. Together, we are committed to advancing groundbreaking therapies that promise to transform patient outcomes in AL Amyloidosis and select immune-mediated diseases.
GOING BEYOND AL
STOCK INFORMATION
STOCK PRICE
STOCK CHART
HISTORICAL DATA
SEC FILINGS
GOVERNANCE
GOVERNANCE DOCUMENTS
CHARTERS
ANALYST COVERAGE
EDISON RESEARCH
H.C. WAINWRIGHT
THINKEQUITY
INVESTORS FAQS
Our corporate headquarters are in Los Angeles, California.
Philadelphia Stock Transfer, Inc.
2320 Haverford Road, Suite 230,
Ardmore, PA 19003
(484) 416-3124
30 Rockefeller Plaza
New York, NY 10112
T: +1.212.653.8700
F: +1.212.653.8701